Andamertinib

Phase 2

FFudan University

Andamertinib is one of 50 therapeutic programs targeting Non-Small Cell Lung Carcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Non-Small Cell Lung CarcinomaNot yet recruiting

Non-Small Cell Lung CarcinomaPhase 2

Not yet recruiting

Competition

Competitive Landscape

51 competitors in Non-Small Cell Lung Carcinoma

#DrugCompanyPhaseTrials

Retevmo

Rozlytrek

Lumakras

Tabrecta

Keytruda

4 6

Taxol

Teva

Phase 3

4 7

Krazati

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Tepmetko

Abraxane

2 10

Imjudo

AstraZeneca

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2029

Phase 2Not yet recruiting

Non-Small Cell Lung Carcinoma

NCT07780578

Clinical

Trials by Indication[1]

Non-Small Cell Lung Carcinoma1 trial

A Single Arm, Multicenter, Phase II Clinical Study to Evaluate the Efficacy and Safety of Andamertinib Combined With Anlotinib in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer Who Failed Prior First Line Third Generation EGFR TKI Therapy

Not yet recruiting·FFudan University·Phase 2·NCT07780578·34 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Andamertinib. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Andamertinib. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Fudan University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: FFudan University

Andamertinib

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2029

Trials by Indication[1]

Non-Small Cell Lung Carcinoma1 trial

References

Drug Info

Quick Facts

Related News